



Spectrum of Movement Disorders of Late-Onset Niemann-Pick Disease Type C

Jasmine Parihar , Deepa Dash , Bhawana Aggarwal, Madhulika Kabra, Roopa Rajan, Deepti Vibha, Rajesh Kumar Singh, Rohit Bhatia, Neerja Gupta, Manjari Tripathi

ABSTRACT: Niemann-Pick disease type C (NPC), is a rare lysosomal storage disorder, which has a variable presentation based on the age of onset. We describe five adult/adolescent-onset NPC cases presenting with a range of movement disorders along with vertical supranuclear gaze palsy as part of the clinical presentation. A diagnostic delay of 4–17 years from the symptom onset was found in this case series. A high index of clinical suspicion in adult/adolescent patients presenting with vertical supranuclear gaze palsy along with various movement disorder phenomenology can help in the early diagnosis of NPC.

RÉSUMÉ: Spectre des troubles du mouvement dans la maladie de Niemann-Pick de type C, d'apparition tardive. La maladie de Niemann-Pick de type C (NPC) est un trouble lysosomal rare de surcharge, dont les manifestations varient selon l'âge auquel apparaissent les premiers symptômes. Seront exposés dans l'article 5 cas de la maladie de NPC dont les symptômes sont apparus soit à l'adolescence, soit à l'âge adulte, et dont le tableau clinique comprenait divers troubles du mouvement et une paralysie verticale supranucléaire du regard. Il s'est écoulé de 4 à 17 ans entre l'apparition des premiers symptômes et la pose du diagnostic dans la série de cas ici étudiée. Aussi faudrait-il savoir envisager la possibilité de la maladie de NPC chez les adolescents et les adultes qui présentent une paralysie verticale supranucléaire du regard et divers troubles du mouvement en vue d'une pose précoce du diagnostic.

Keywords: *NPC1*, *NPC2*, Movement disorders, Niemann-Pick, Dystonia

doi:[10.1017/cjn.2021.222](https://doi.org/10.1017/cjn.2021.222)

Can J Neurol Sci. 2022; 49: 804–808

Niemann-Pick disease type C (NPC) is a rare autosomal recessive lysosomal storage disorder with pathogenic mutations in either the *NPC1* gene on chromosome 18 (95% of cases) or the *NPC2* gene on chromosome 14 (5% of cases).¹ The age of onset and clinical presentation of NPC is highly variable, ranging from a perinatal presentation with rapidly progressive acute liver or respiratory failure to rare adult-onset chronic progressive neurodegenerative form.

The overall incidence of NPC is 0.35–2.2 per 100,000.² However, the incidence and clinical presentation in adults has not been well delineated with only a few case reports and case series available in literature. We report five adult-onset NPC cases from India, presenting with various movement disorders.

An eighteen-year-old male presented with gradually worsening academic performance and behavioral disturbance for 3 years (Case 1). He was first evaluated at 15 years of age, when he had left upper limb dystonia with mild cerebellar dysfunction along with declining scholastic performance. At 18 years, he had further decline in his cognitive and balance troubles with worsening dystonia progressing to left hemi-body (Video 1) with facial and

perioral involvement. Development of myoclonus, vertical supranuclear gaze palsy (VSGP) (Video 2), and splenomegaly led to the suspicion of NPC with an NPC suspicion score (NPC-SS) of 140.

Brain MRI showed nonspecific findings of mild T2/FLAIR hyperintensities in bilateral posterior parietal lobes. Bone-marrow aspiration demonstrated foamy macrophages. Clinical exome sequencing showed compound heterozygous variants in the *NPC1* gene. Table 1 summarizes the phenotypic characteristics and investigations, including exome sequencing of our patients.

A 42-year-old female had a gradually worsening difficulty in looking downwards and upper limb tremors since the age of 25 years (Case 2). After 8 years of symptom onset, she developed gradual apathy, withdrawal, and memory loss along with bradykinesia, dysarthria, and urinary incontinence. The patient's elder sister had a similar cognitive disturbance with onset at 22 years and wandered off from home after 5 years of disease onset. First examined at the age of 42 years, the patient had an MMSE score of 14/30 with predominant frontal dysfunction. She had slow saccades, broken pursuits, and VSGP involving downgaze more than upgaze. The examination also revealed bradykinesia, upper

From the Department of Neurology, All India Institute of Medical Sciences, New Delhi, India (JP, DD, RR, DV, RKS, RB, MT); and Division of Genetics, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India (BA, MK, NG)

RECEIVED APRIL 28, 2021. FINAL REVISIONS SUBMITTED SEPTEMBER 4, 2021. DATE OF ACCEPTANCE SEPTEMBER 10, 2021.

Correspondence to: Dr. D. Dash, MD, DM, Department of Neurology, All India Institute of Medical Sciences, New Delhi, India. Email: drddash@yahoo.com

Table 1: Clinical characteristics and investigations of patients with NPC

	Case 1	Case 2	Case 3	Case 4	Case 5
<i>Clinical features</i>					
Age of onset	15 years	25 years	21 years	27 years	30 years
Disease duration before diagnosis	3 years	17 years	8 years	4 years	4 years
Consanguinity	No	No	No	No	No
<i>Neurological manifestations</i>					
Cognitive impairment	Yes	Yes	Yes	Yes	Yes
Cerebellar ataxia	Yes	Yes	Yes	Yes	No
Myoclonus	Yes	Yes	No	Yes	No
VSGP	Yes	Yes	Yes	Yes	Yes
Dysarthria/dysphagia	Yes/no	Yes/no	Yes/no	No/no	No/no
Dystonia type	Unilateral upper limb dystonia at the onset. Later progressed to hemidystonia	Unilateral foot dystonia	Blepharospasm	Asymmetrical upper limb and facial dystonia	Multifocal dystonia that progressed to generalized dystonia
Chorea	No	Yes	No	No	No
Tremors	No	Yes- rest, postural and intention tremors	No	Yes- intention tremors.	No
Parkinsonism	No	Yes	No	No	Yes
Organomegaly	Yes	No	Yes	No	Yes
Psychiatric symptoms	Yes	No	No	Yes	Yes
<i>Investigations</i>					
Genetic test results	<i>NPC1</i> compound heterozygous	<i>NPC2</i> homozygous	<i>NPC2</i> Homozygous	<i>NPC1</i> compound heterozygous	<i>NPC2</i> homozygous
Mutation	c.3230G>C in Exon 21 and c.800C>A in exon 6	c.358C>A in exon 3	c.358C>A in exon 3	c.2974G>C in Exon20 and c.1628delC in exon 10	c.358C>A in exon 3
Amino acid change	p. Arg1077Pro and p. Ala267Asp	p. Pro120Thr	p. Pro120Thr	p.G992R and p.P543Rfs*20	p. Pro120Thr
ACMG classification	VUS	LP	LP	P	LP
Foamy macrophages/sea blue histiocytes on bone marrow aspiration or biopsy	Present	Present	Present	Present	Absent
MRI brain	Normal	Frontal predominant cerebral and cerebellar atrophy	diffuse cerebral atrophy with paucity of underlying white matter	Normal	Mild diffuse cerebral atrophy
NPC suspicion score	140	140	90	120	90

ACMG: The American College of Medical Genetics and Genomics; LP: Likely pathogenic; P: Pathogenic; VUS: variants of uncertain significance.

*Clinical exome sequencing was performed in all the five cases (It covers 8332 genes including the most relevant disease-associated genes from OMIM, HGMD, Clinvar and Swissvar). Sanger confirmation was done for all the novel variants.

limb rest, postural and intention tremors, hypophonia, and unilateral foot dystonia along with bilateral upper limb choreiform movements with cortical myoclonus in distal upper limbs. Bone marrow aspiration showed abundant foamy histiocytes (Figure 1a, b), and skin biopsy showed perivascular histiocytic infiltration (Figure 1c). MRI brain showed marked frontal predominant atrophy (Figure 1d). Exome sequencing showed a novel homozygous variant in exon 3 of the *NPC2* gene (Table 1).

Twenty-nine-year-old male had progressive gait disturbance along with cognitive decline in the form of executive dysfunction along with apathy beginning at the age of 21 years (Case 3). He developed apraxia early in the disease course with difficulty in

using gadgets and simple tools followed by progressive gait disturbance with swaying while walking and unprovoked falls. He had spastic dysarthria, VSGP (prominently involving down-gaze), and axial and appendicular cerebellar ataxia. The patient also had distal myoclonus, blepharospasm, and mild hepatomegaly with an NPC-SS of 90. Brain MRI showed cerebral atrophy with confluent T2/FLAIR hyperintensities in deep white matter (Figure 1e, f).

Thirt-one-year-old female had intentional tremors of hands for the past 4 years, leading to a significant change in her handwriting (Case 4). This was followed by cerebellar ataxia and dystonic posturing of the left hand that increased on walking. In the past




Figure 1: Bone marrow aspiration of case 2 showing foamy macrophages at 100× (a) and 400× (b) magnification. Skin biopsy at 400× magnification showing perivascular infiltration of histiocytes (c). MRI brain showing axial FLAIR image with predominant frontal atrophy in case 2 (d). Axial FLAIR (e) and T2 image (f) of case 3 showing periventricular hyperintensities along with diffuse atrophy.

year, she developed memory problems and depressive symptoms. The vertical saccades were slow, and pursuits were broken with downgaze VSGP. She had mild upper limb cogwheel rigidity with asymmetrical upper limb and facial dystonia. She had distal, rapid, jerky movements suggestive of cortical myoclonus in both upper limbs (Video 3). The examination also revealed pan-cerebellar dysfunction with brisk deep tendon reflexes.

A 34-year-old male presented with a 4-year history of gradual difficulty in planning, calculation, and handling finances (Case 5). One year after symptom onset, he had social disinhibition, inappropriate sexual behavior, and emotional lability. After an year of onset, he developed left lower limb dystonia that progressed to generalized dystonia involving all four limbs and the trunk. Additionally, examination revealed appendicular rigidity, slow saccades, and VSGP. His MMSE was 26/30, with frontal and parietal lobe dysfunction. Splenomegaly was found clinically and confirmed on ultrasound.

NPC is a multisystem disease with a wide range of psychiatric, neurological, and visceral manifestations. The adult-onset form of the disease is rare, and only a few case series have been reported (Table 2).

In an international disease registry, 27% patients had adolescent/adult-onset.¹ The mean age of onset of symptoms in our series of adult/adolescent onset of NPC patients was 20.7 years (range 10–30 years), which is similar to the age of onset of

neurological or psychiatric manifestations reported previously for adult patients with NPC^{3,4}. Late adult-onset of NPC has been rarely reported.⁵ A diagnostic delay of 4–17 years was found in our case series, likely due to a low index of suspicion, nonspecific phenotype, and a lack of well-defined diagnostic criteria. Table 2 compares the current series' clinical profile with that of two large adult-onset NPC series.

Among adults, movement disorders have been reported in 58–62% of patients.^{3,4} Dystonia, the most common movement disorder in NPC, is reportedly more commonly in adults than children.³ All of our patients had one or more type of movement disorder as part of their clinical presentation probably because of their recruitment from the movement disorder clinic. There is variability in the percentage of patients who had dystonia as a clinical feature based on the type of patients enrolled. In a study that screened patients with cerebellar ataxia and cognitive decline for *NPCI* mutations screening, only one patient had dystonia whereas in other cases series of adult/adolescent-onset NPC, 40% of patients had dystonia.^{6,7} In contrast, dystonia was part of the clinical spectrum in all of our patients. Cerebellar ataxia has been found to be the commonest movement disorder in a previous case series but was the second most common movement disorder in our case series.⁷ Four of our patients had cerebellar ataxia, two had tremors and one had chorea. NPC patients can have different

Table 2: Clinical characteristics of adult patients with NPC in different serie

Clinical feature	Sevin et al. ³ (N = 68), n (%)	Bonnet et al. ⁴ (N = 37), n (%)	Current series (N = 5), n (%)
Psychiatric	26 (38)	37 (100)	3 (60)
Ataxia	52 (76)	33 (89)	4 (80)
VSGP	52 (76)	31 (84)	5 (100)
Cognitive disorder	42 (61)	29 (78)	5 (100)
Dysarthria	43 (63)	33 (89)	3 (60)
Dysphagia	28 (41)	22 (60)	0
Movement disorder			
Dystonia	39 (57)	23 (62)	5 (100)
Parkinsonism	7 (10)	–	2 (40)
Chorea	14 (20)	–	1 (20)
Tremors	–	–	2 (40)
Blepharospasm	–	–	1 (20)
Cataplexy	3 (4)	0	0
Deafness	3 (4)	–	0
Epilepsy	11 (16)	5 (13)	0
Pyramidal	13 (19)	–	2 (40)
Splenomegaly	37 (54)	–	2 (40)
Hepatomegaly	13 (19)	–	0

VSGP- vertical supranuclear gaze palsy.

kinds of myoclonus including rhythmic cortical myoclonus, stimulus-sensitive myoclonus, and myoclonic storm.⁷ The patients in our series had clinical features in keeping with cortical myoclonus. Similar to other series, hyperkinetic movement disorders were dominant in our case series and only two patients had parkinsonism.⁷

Psychiatric manifestations have been reported in 25–45% of patients with NPC, including depression, apathy, delusions, hallucinations, self-mutilation, bipolar disorders, and obsessive-compulsive disorders.^{1,3,4} Three of our patients had psychiatric symptoms. Early-onset psychiatric manifestations without other neurological features can lead to a delay in diagnosis and could be challenging to manage. Additionally, if neuroleptics are used to manage the psychiatric symptoms, it could be a challenge to discern the etiology of movement disorders from drug-induced dyskinesia.

Cognitive dysfunction has been reported in 61% of 68 adult patients with NPC.⁴ Similar to our series, frontal lobe dysfunction, apathy and mutism, aphasia, apraxia, and memory impairment have been reported in late-onset NPC cases, with frontal dysfunction being the most common.^{3,4}

Brainstem and cerebellar dysfunction in the form of VSGP, dysarthria, dysphagia, gelastic cataplexy, deafness, and ataxia are the key features that should point toward the diagnosis of NPC. Movement disorders, VSGP, dysarthria, and ataxia are more common in late-onset NPC and has been reported in large proportion of patients in all the case series (Table 2).^{3,4} Vertical supranuclear saccade palsy with isolated vertical saccade initiation delay (Video 2) is a clinical hallmark of the adult-onset

disease that may help in earlier diagnosis of this rare disorder. As the disease progresses, VSGP emerges.

Bone marrow aspirate is a relatively accessible tissue to demonstrate the lipid storage that is the hallmark of the disease. Foamy macrophages/sea blue histiocytes were seen in four out of five of our cases. However, with increasing availability of the genetic testing, this invasive test is not necessary for diagnosis. NPC suspicion index is a tool which aids in screening for patients with a high likelihood of NPC for further diagnostic evaluation. A score ≥ 70 should warrant NPC genetic testing.⁸

About 550 NPC1 and 29 NPC2 variants have been reported to date (The Human Gene Mutation Database, <http://www.hgmd.cf.ac.uk/ac/index.php>). The p.Gly992Arg pathogenic variant in the *NPC1* gene found in one of our cases, resulting in c.2974G>C, has been reported previously in multiple individuals with Niemann-Pick disease type C.^{9,10} Three of our patients showed novel homozygous missense variation in exon 3 of the *NPC2* gene (chr14:74951123G>T; c.358C>A) resulting in substitution of Threonine for Proline at codon 120 (p.Pro120Thr). Different missense variation c.358C>T (rs104894458) that causes p.Pro120Ser has been reported in Iranian patients with juvenile/adult-onset disease with slow progression, similar to our cases.¹¹ The novel change c.358C>A, found in three of our patients, seems to be a common variant in the Indian population with late-onset NPC and needs further exploration.

NPC is a rare neurodegenerative disease with a broad spectrum of clinical manifestations. A high index of suspicion for NPC should be kept for patients presenting with movement disorders like dystonia, ataxia along with VSGP irrespective of the age of presentation.

ETHICS STATEMENT

Informed consent was obtained from all the subjects for publication.

STATEMENT OF AUTHORSHIP

JP: Drafted the manuscript, Management of the patient
 DD: Concept, review and editing of manuscript, Management of the patient
 BA: Editing the genetics part of the manuscript
 MK: Editing the genetics part of the manuscript
 RR: Editing the manuscript, management of the patients
 DV: Editing the manuscript, management of the patients
 RKS: Editing the manuscript, management of the patients
 RB: Editing the manuscript, management of the patients
 NG: Editing the genetics part of the manuscript
 MT: Editing the manuscript, management of the patients

DISCLOSURES

The authors have no conflicts of interest to declare.

SUPPLEMENTARY MATERIAL

To view supplementary material for this article, please visit <https://doi.org/10.1017/cjn.2021.222>.

REFERENCES

1. Patterson MC, Mengel E, Wijburg FA, et al. Disease and patient characteristics in NP-C patients: findings from an international disease registry. *Orphanet J Rare Dis.* 2013;8:12.
2. Vanier MT, Millat G. Niemann-Pick disease type C. *Clin Genet.* 2003;64:269–81.
3. Bonnot O, Gama CS, Mengel E, et al. Psychiatric and neurological symptoms in patients with Niemann-Pick disease type C (NP-C): findings from the international NPC registry. *World J Biol Psychiatry.* 2019;20:310–9.
4. Sévin M, Lesca G, Baumann N, et al. The adult form of Niemann-Pick disease type C. *Brain.* 2007;130:120–33.
5. Kumar N, Rizek P, Mohammad Y, Jog M. Pearls & Oy-sters: Niemann-Pick disease type C in a 65-year-old patient. *Neurology.* 2016;87:e79–81.
6. Schicks J, Muller vom Hagen J, Bauer P, et al. Niemann-Pick type C is frequent in adult ataxia with cognitive decline and vertical gaze palsy. *Neurology.* 2013;80:1169–117.
7. Anheim M, Lagha-Boukbiza O, Fleury-Lesaunier MC, et al. Heterogeneity and frequency of movement disorders in juvenile and adult-onset Niemann-Pick C disease. *J Neurol.* 2014;261:174–9.
8. Wijburg FA, Sedel F, Pineda M, et al. Development of a Suspicion Index to aid diagnosis of Niemann-Pick disease type C. *Neurology.* 2012;78:1560–7.
9. Millat G, Marçais C, Tomasetto C, et al. Niemann-Pick C1 disease: correlations between *NPC1* mutations, levels of NPC1 protein, and phenotypes emphasize the functional significance of the putative sterol-sensing domain and of the cysteine-rich luminal loop. *Am J Hum Genet.* 2001;68:1373–85.
10. Sedel F, Chabrol B, Audoin B, et al. Normalisation of brain spectroscopy findings in Niemann-Pick disease type C patients treated with miglustat. *J Neurol.* 2016;263:927–36.
11. Alavi A, Nafissi S, Shamshiri H, Nejad MM, Elahi E. Identification of mutation in *NPC2* by exome sequencing results in diagnosis of Niemann-Pick disease type C. *Mol Genet Metab.* 2013;110:139–44. DOI [10.1016/j.ymgme.2013.05.019](https://doi.org/10.1016/j.ymgme.2013.05.019).